| Nov 13 |
INmune Bio Inc. Announces Final Enrollment of 208 Patients in Phase 2 Trial in Early Alzheimer's Disease
|
| Nov 3 |
INmune Bio Third Quarter 2024 Earnings: US$0.60 loss per share (vs US$0.48 loss in 3Q 2023)
|
| Nov 1 |
INmune Bio Inc (INMB) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges and ...
|
| Nov 1 |
INmune Bio, Inc. (INMB) Q3 2024 Earnings Call Transcript
|
| Oct 31 |
INmune Bio GAAP EPS of -$0.60 misses by $0.10
|
| Oct 31 |
INmune Bio Inc. Announces Third Quarter 2024 Results and Provides Business Update
|
| Oct 30 |
INmune Bio Q3 2024 Earnings Preview
|
| Oct 28 |
INmune Bio Inc. to Host Webinar on Cognitive Testing Using EMACC and CDR-SB
|
| Oct 11 |
INmune Bio Inc. to Participate in the Maxim Healthcare Virtual Summit
|
| Oct 9 |
INmune Bio Inc (INMB) Q2 2024 Earnings Call Highlights: Promising Advances Amid Rising Costs
|
